Mobile

Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus intramuscular administration of GlaxoSmithKline Biologicals’ combined measles...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-005944-22

Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus intramuscular administration of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) to healthy children aged 11 to 21 months

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate GMT and seroconversion rate to VZV before and after intramuscular and subcutaneous injection of GSK’s MeMuRu-OKA vaccine.

Critère d'inclusion

  • Active immunization of healthy children aged 11 to 21 months against measles, mumps, rebella and varicella diseases

Liens